Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582525 | 0.88 | CTSV (0.50) | BRD4CTSVCTSL | |
| SCHEMBL11922624 | 0.82 | ALDH1A1 (0.47) | BRD4CTSVCTSLMAPK1SMN1; SMN2 | |
| SCHEMBL2684142 | 0.79 | NPC1 (0.55) | BRD4CTSVCTSLMAPK1SMN1; SMN2 | |
| SCHEMBL2684149 | 0.77 | ALDH1A1 (0.49) | BRD4PPIAALOX15SMN1; SMN2HSD17B10 | |
| SCHEMBL4503743 | 0.77 | ALOX15 (0.50) | PDE4BALOX15 | |
| SCHEMBL23901157 | 0.74 | OPRK1 (0.53) | PDE4BALOX15 | |
| SCHEMBL2682298 | 0.74 | CTSV (0.49) | BRD4PPIACTSVCTSLSMN1; SMN2 | |
| SCHEMBL23796824 | 0.73 | MEN1 (0.60) | PPIAMAPK1 | |
| SCHEMBL1693608 | 0.70 | PDE4B (0.58) | PDE4BALOX15MAPK1NPSR1 | |
| SCHEMBL6799507 | 0.70 | GAA (0.49) | PDE4BALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| WO-2010116088-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | CYP27B1, NDUFB3, MT-ND5 | PDE4B 893/4885BRD4 632/4885PPIA 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.